If you are a small business and are interested in obtaining early-stage financing to support your cancer research and technology development, you may be in luck. The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are offering funding opportunities to eligible small businesses and research institutions for […]
“Who do you think was the country’s biggest supplier of prescription drugs in 2007? Was it Pï¬zer or Merck or Bristol-Meyers-Squib or Novartis? No. It was Teva Pharmaceuticals, a generic manufacturer.” ~ Martin Voet, The Generic Challenge: Understanding Patents, FDA & Pharmaceutical Life-Cycle Management (Second Edition). The Generic Challenge is about providing the necessary […]
Therapies for Ignored Diseases Last week, the Bill and Melinda Gates Foundation gave Collaborative Drug Discovery (CDD) a $1.9 million grant to help tuberculosis scientists to collaborate to discover new cures for TB, a disease that is resurgent in the 3rd world. The company provides web-based software that organizes preclinical research data to enable scientists […]
As Congress is considering possible legislation to create an abbreviated pathway for the FDA to approve generic biologic therapies (“biogeneric,” “biosimilar” and “follow-on biologics”), differences in the R&D expense and product cost, and the potential for both new therapies post-approval and second-generation innovations have raised questions about how to achieve the proper balance between innovation […]
In another blow against late claiming, the Court of Appeals for the Federal Circuit denied an appeal from a re-examination because the patent applicants “could have filed the present claims” earlier in the application. Although I suspect the court was just ticked off because the applicants appeared to be gaming the system – the reexamination […]
As mentioned in the AmLaw Daily, Dennis Crouch’s Patently-O blog reported on a newly published patent application by Halliburton Energy Services. The patent application has claims to what can only be described as a method of doing business when your business is patent trolling, i.e., getting rights to a patent and asserting it against infringers. […]
Now that it appears that we are in a recession — and there’s no good way to nuance that anymore — what does is mean for the legal profession? The legal area was once considered recession-proof with some areas even going up as companies focus on competitors. Now, the demand for legal services is certainly […]
cul·ture (n.) the set of shared attitudes, values, goals, and practices that characterizes an institution or organization (Merriam-Webster’s Dictionary Online). The book “Intellectual Property Culture: Strategies to Foster Successful Patent and Trade Secret Practices in Everyday Business” by Eric Dobrusin and Ronald Krasnow is much better than its bland title or cover would belie. This […]
Served Up Daily
Editor-in-Chief Barista Stephen Jenei is a patent attorney and Owner of Jenei LLC. When not serving up patent chat over a steaming cup of java, he's handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields. More info @ Jenei LLC
